Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD

Core Insights - Apogee Therapeutics, Inc. has appointed Dr. Lisa Bollinger to its board of directors, bringing over 30 years of experience in drug development and regulatory affairs [1][2][3] - The company is advancing its clinical pipeline for atopic dermatitis, chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications, with two programs currently in clinical development and a third expected in the second half of 2024 [2][4] Company Overview - Apogee Therapeutics is a clinical-stage biotechnology company focused on developing differentiated biologics for high unmet needs in atopic dermatitis, COPD, asthma, and other inflammatory and immunology conditions [4] - The company's advanced programs, APG777 and APG808, are designed to improve upon existing therapies by targeting established mechanisms of action and utilizing advanced antibody engineering to enhance properties such as half-life [4] Leadership and Expertise - Dr. Bollinger's previous roles include Vice President of Regulatory Affairs at Merck and significant experience at Amgen and the U.S. FDA, where she oversaw pediatric drug development and safety [1][2][3] - The leadership team at Apogee is positioned to leverage Dr. Bollinger's regulatory insights and clinical expertise to navigate the complexities of drug development and regulatory approval processes [2][3]